Pharmaceutical - Ferrer Internacional

Filter

Current filters:

Ferrer Internacional

Popular Filters

Medimetriks licenses ozenoxacin, a novel antibacterial, from Ferrer

24-03-2014

US specialty drug firm Medimetriks Pharmaceuticals has entered into a licensing agreement with Ferrer,…

Antibiotics and Infectious diseasesFerrer InternacionalLicensingMedimetriks PharmaceuticalsNorth AmericaOzenoxacinPharmaceuticalUSA

Ferrer links with Ildong and Ergomed for lorediplon development

03-02-2014

Privately-held Spanish drugmaker Ferrer has executed two agreements, one with South Korea’s Ildong…

Asia-PacificErgomed Clinical ResearchFerrer InternacionalIldong PharmaLicensinglorediplonNeurologicalPharmaceuticalResearch

Planned expansion of anti-psychotic drug throughout Europe

29-10-2013

Austrian drugmaker AOP Orphan and privately held Spanish drugmaker Ferrer Internacional are expanding…

AdasuveAOP OrphanEuropeFerrer InternacionalMarkets & MarketingNeurologicalPharmaceutical

Ferrer and Medivir join forces on Adasuve for Nordic markets

19-09-2013

Sweden’s Medivir (Nasdaq OMX: MVIR) and privately-held Spanish drugmaker Ferrer Internacional have…

AdasuveAlexza PharmaceuticalEuropeFerrer InternacionalLicensingMedivirNeurologicalPharmaceutical

Ferrer's Ozenoxacin shows superiority in Ph III impetigo trial

05-06-2013

Privately-held Spanish drugmaker Ferrer Internacional says that it has successfully completed a Phase…

Antibiotics and Infectious diseasesDermatologicalsFerrer InternacionalLicensingOzenoxacinPharmaceuticalResearch

Positive EU regulatory news for Alexza and Ferrer, but not Gentium

22-02-2013

USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) and Spanish partner Grupo Ferrer Internacional have received…

AdasuveAlexza PharmaceuticalBiotechnologydefibrotideEuropeFerrer InternacionalGentiumNephrology and HepatologyNeurologicalPharmaceuticalRegulation

Positive recommendations from EMA's CHMP for Selincro, Adasuve and Perjeta

17-12-2012

Last week's deliberations of the European Medicines Agency's Committee for Medicinal Products for Human…

AdasuveAlexza PharmaceuticalBiotechnologyEuropeFerrer InternacionalLundbeckNeurologicalOncologyPerjetaPharmaceuticalRegulationRocheSelincro

FDA sets PDUFA date for Alexza's resubmission for Adasuve

08-07-2012

Following two earlier rejections, the US Food and Drug Administration has now accepted Alexza Pharmaceuticals…

AdasuveAlexza PharmaceuticalFerrer InternacionalNeurologicalNorth AmericaPharmaceuticalRegulation

Janssen files for EU approval of canagliflozin in type 2 diabetes; Ferrer pulls Egrifta MAA

27-06-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) European subsidiary Janssen-Cilag International…

Anti-viralscanagliflozinDiabetesEgriftaEuropeFerrer InternacionalJanssenJohnson & JohnsonPharmaceuticalRegulation

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top